Oncolytics Biotech Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONC.TO research report →
Companywww.oncolyticsbiotech.com
Oncolytics Biotech Inc. , a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
- CEO
- Wayne F. Pisano
- IPO
- 2000
- Employees
- 28
- HQ
- Calgary, AB, CA
Price Chart
Valuation
- Market Cap
- $142.25M
- P/E
- -3.90
- P/S
- 0.00
- P/B
- -23.83
- EV/EBITDA
- -3.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 4596.70%
- ROIC
- -1067.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-31,710,000 · -14.26%
- EPS
- $-0.41 · 0.00%
- Op Income
- $-34,982,000
- FCF YoY
- 4.40%
Performance & Tape
- 52W High
- $2.08
- 52W Low
- $0.45
- 50D MA
- $1.31
- 200D MA
- $1.08
- Beta
- 1.48
- Avg Volume
- 285.77K
Get TickerSpark's AI analysis on ONC.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ONC.TO Coverage
We haven't published any research on ONC.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONC.TO Report →